Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Indrė Kučinskaitė-Kodzė, Martynas Simanavičius, Aistis Šimaitis, Aurelija Žvirblienė
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 serological monitoring IgG/IgM dynamics longitudinal study Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/8fdc3dfbdc3f401abd031f2753e67844
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fdc3dfbdc3f401abd031f2753e67844
record_format	dspace
spelling	oai:doaj.org-article:8fdc3dfbdc3f401abd031f2753e678442021-11-25T19:14:29ZPersistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection10.3390/v131123131999-4915https://doaj.org/article/8fdc3dfbdc3f401abd031f2753e678442021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4915/13/11/2313https://doaj.org/toc/1999-4915Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA. Results: Six months after the outbreak, 95% (CI 86–99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69–91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic. Conclusions: Detectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases.Indrė Kučinskaitė-KodzėMartynas SimanavičiusAistis ŠimaitisAurelija ŽvirblienėMDPI AGarticleSARS-CoV-2serological monitoringIgG/IgM dynamicslongitudinal studyMicrobiologyQR1-502ENViruses, Vol 13, Iss 2313, p 2313 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 serological monitoring IgG/IgM dynamics longitudinal study Microbiology QR1-502
spellingShingle	SARS-CoV-2 serological monitoring IgG/IgM dynamics longitudinal study Microbiology QR1-502 Indrė Kučinskaitė-Kodzė Martynas Simanavičius Aistis Šimaitis Aurelija Žvirblienė Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
description	Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA. Results: Six months after the outbreak, 95% (CI 86–99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69–91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic. Conclusions: Detectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases.
format	article
author	Indrė Kučinskaitė-Kodzė Martynas Simanavičius Aistis Šimaitis Aurelija Žvirblienė
author_facet	Indrė Kučinskaitė-Kodzė Martynas Simanavičius Aistis Šimaitis Aurelija Žvirblienė
author_sort	Indrė Kučinskaitė-Kodzė
title	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_short	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_full	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_fullStr	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_full_unstemmed	Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_sort	persistence of sars-cov-2-specific antibodies for 13 months after infection
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/8fdc3dfbdc3f401abd031f2753e67844
work_keys_str_mv	AT indrekucinskaitekodze persistenceofsarscov2specificantibodiesfor13monthsafterinfection AT martynassimanavicius persistenceofsarscov2specificantibodiesfor13monthsafterinfection AT aistissimaitis persistenceofsarscov2specificantibodiesfor13monthsafterinfection AT aurelijazvirbliene persistenceofsarscov2specificantibodiesfor13monthsafterinfection
_version_	1718410105915965440

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Ejemplares similares